This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bodary, P. F. Articles by Eitzman, D. T. Search for Related Content PubMed PubMed Citation Articles by Bodary, P. F. Articles by Eitzman, D. T.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:235.)
© 2006 American Heart Association, Inc.

Editorials

Adiponectin

Vascular Protection From the Fat?

Peter F. Bodary; Daniel T. Eitzman

From the Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical Center, Ann Arbor.

Correspondence to Daniel Eitzman, University of Michigan Medical Center, 1150 Medical Center Dr, Ann Arbor, MI 48109-0644.

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The obesity pandemic will likely have a significant impact on the global incidence of cardiovascular disease. Although the mechanisms linking obesity and cardiovascular disease are unclear, recent studies have implicated the adipocyte as a potentially important mediator of vascular complications. The adipocyte is no longer considered a passive storage depot for triglycerides and fatty acids, but rather an active metabolic organ capable of producing several factors, commonly referred to as adipocytokines or adipokines, that may have effects on many physiological and pathophysiological processes. With increasing fat mass, several adipose-related factors are upregulated that may affect local and distant inflammatory processes, including atherothrombosis.^1–3 However, the most abundant known factor produced by the adipocyte, adiponectin, appears to be downregulated in most cases associated with increasing fat mass.⁴ Although most adipokines are thought to promote vascular disease, several studies over the past few years indicate adiponectin is actually protective against vascular disease.³

See page 224

Adiponectin, (also known as adipoQ, adipocyte complement-related protein of 30kD [ACRP30], adipose most abundant gene transcript-1 [apM1],⁵ and GBP28⁶), was cloned using subtractive hybridization techniques from a cDNA library of differentiating adipocytes and first published in 1995.⁷ Although the clinical implications of this protein were unknown at the time, the authors recognized that its very high plasma concentration (&10 µg/mL) suggested that it may have actions beyond local adipocyte differentiation.⁷ Since the discovery of adiponectin, adiponectin receptors (AdipoR1 and AdipoR2) have also been identified from liver and skeletal muscle, and these receptors have been shown to mediate . . . [Full Text of this Article]

This article has been cited by other articles:

				N. Sattar, G. Wannamethee, N. Sarwar, J. Tchernova, L. Cherry, A. M. Wallace, J. Danesh, and P. H. Whincup Adiponectin and Coronary Heart Disease: A Prospective Study and Meta-Analysis Circulation, August 15, 2006; 114(7): 623 - 629. [Abstract] [Full Text] [PDF]